Alnylam Pharmaceuticals, Inc. (ALNY) Reports Q3 Loss of 31c/Share
Tweet
Share
E-mailGet Alerts ALNY Hot Sheet
Price: $294.06 +2.04%
EPS Growth %: +409.4%
Financial Fact:
Unrealized (loss) gain on marketable securities: -18.33M
Today's EPS Names:
DTGI, CRMT, MAYS, More
EPS Growth %: +409.4%
Financial Fact:
Unrealized (loss) gain on marketable securities: -18.33M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) reported Q3 EPS of ($0.31), $0.04 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $20.8 million versus the consensus estimate of $20.51 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MillerKnoll, Inc. (MLKN) Tops Q4 EPS by 4c
- Micron Technology (MU) Tops Q3 EPS by $4.62, Guidance Beats
- Worthington Industries (WOR) Misses Q4 EPS by 9c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
